- Home
- TRAW
TRAW
TRAWS PHARMA INC
as 04-24-2025 11:43am EST
Stocks
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | NEWTOWN |
| Market Cap: | 10.1M | IPO Year: | 2013 |
| Target Price: | N/A | AVG Volume (30 days): | 55.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -35.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.52 - $19.44 | Next Earning Date: | 05-14-2025 |
| Revenue: | $226,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 3.81% | Revenue Growth (next year): | 30.43% |
Latest TRAWS PHARMA INC News
TRAW Breaking Stock News: Dive into TRAW Ticker-Specific Updates for Smart Investing
GlobeNewswire
24 days ago
Traws Pharma Reports Full Year 2024 Results and Business Highlights
GlobeNewswire
a month ago
Traws Pharma Announces Management Updates
GlobeNewswire
a month ago
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
GlobeNewswire
a month ago
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
GlobeNewswire
a month ago
Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates
GlobeNewswire
a month ago
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
GlobeNewswire
2 months ago
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
GlobeNewswire
2 months ago
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
Compare TRAW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRAW TRAWS PHARMA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.